For example, DLL3 has emerged as a critical therapeutic target for SCLC, with related antibody‐drug conjugates and bispecific T‐cell engagers demonstrating promising anti‐tumour activity in clinical trials.198. Here, DLL3 is linked to small cell lung carcinoma.